Aquestive Therapeutics (AQST) Operating Leases (2020 - 2026)

Aquestive Therapeutics' Operating Leases history runs 7 years deep, the most recent figure standing at $4.8 million for Q1 2026.

• In Q1 2026, Operating Leases changed 0.02% year-over-year to $4.8 million; the TTM figure through Mar 2026 stood at $4.8 million (changed 0.02% YoY), while the FY2025 annual figure was $4.3 million, down 12.7% from the prior year.
• Operating Leases was $4.8 million for Q1 2026 at Aquestive Therapeutics, up from $4.3 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $6.0 million in Q1 2023 to a low of $2.2 million in Q3 2022.
• Historically, Operating Leases has averaged $4.7 million across 5 years, with a median of $5.1 million in 2022.
• The sharpest annual moves came in 2022 and 2023: Operating Leases decreased 28.21% in 2022, then soared 168.8% in 2023.
• A 5-year view of Operating Leases shows it stood at $5.1 million in 2022, then rose by 6.18% to $5.4 million in 2023, then slipped by 7.98% to $5.0 million in 2024, then decreased by 12.7% to $4.3 million in 2025, then grew by 11.16% to $4.8 million in 2026.
• The last three Operating Leases figures came in at $4.8 million (Q1 2026), $4.3 million (Q4 2025), and $4.5 million (Q3 2025), per Business Quant data.